Objective: Activated microglia are thought to play a major role in cortical gray matter (GM) demyelination in multiple sclerosis (MS). Our objective was to evaluate microglial activation in cortical GM of patients with MS in vivo and to explore its relationship to measures of disability.
Multiple sclerosis (MS) has traditionally been regarded as a white matter (WM) disease, but neuropathologic [1] [2] [3] [4] [5] [6] and magnetic resonance spectroscopic (MRS) and MRI studies [7] [8] [9] have demonstrated substantial damage in the cortical gray matter (GM), which plays a major role in the progression of disability. 6, 10 A characteristic feature of cortical MS lesions is the relative lack of peripheral immune cell infiltrates 2 with prominent microglial activation. 6 However, the consequences of microglial activation in cortical GM in MS are uncertain, and could be a consequence of tissue damage or a major mechanism of cell injury that directly or indirectly cause neuronal dysfunction.
Microglial activation can be visualized in vivo using 11 C-PK11195 (PK11195) PET, 16 but studies have been limited in scope and have characterized WM changes only. [17] [18] [19] PK11195 has been demonstrated to detect activated macrophages and microglia in postmortem tissue 17 by specifically binding to the translocator protein 18KDa (TSPO) that is upregulated with activation. 16, 20 However, until recently, [21] [22] [23] accurate measurements of TSPO binding in the brains of patients with MS have been difficult because of the lack of an anatomically consistent reference region and the limitations of image registration and segmentation procedures due to variable ventricular enlargement and brain atrophy.
Here we have applied improved imageprocessing techniques and PK11195 PET to characterize cortical microglial activation in a cross-sectional study of patients with MS with a range of disabilities in order to test the hypotheses that PK11195 can detect areas of cortical pathology and that increased binding is associated with greater disability.
METHODS Subjects and clinical evaluation.
Ten patients with active relapsing-remitting MS (RRMS) and 8 patients with secondary progressive MS (SPMS) were studied (table 1) . Disability was assessed using the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Impact Scale . Eight healthy subjects, with no history of neurologic or psychiatric illness and not taking medication, served as the control group (5 F; age ϭ 32.9 Ϯ 4.6 years, mean Ϯ SD).
Standard protocol approvals, registrations, and patient consents. Ethical approval was received from the Hammersmith and Queen Charlotte's Research Ethics Committee and permission to administer PK11195 was obtained from the Administration of Radioactive Substances Advisory Committee (ARSAC) of the Department of Health, UK. Written informed consent was obtained from all subjects in accordance with the Declaration of Helsinki.
Scanning procedures. Subjects received PK11195 PET and
MRI no more than 7 days apart. The PK11195 PET scan was performed using a GE Discovery RX PET/CT scanner. 24 The mean injected dose for PK11195 was 360 MBq and scanning began 30 seconds before tracer infusion as an IV bolus, generating 18 time frames of tissue data over 60 minutes.
Subjects were positioned supine with their transaxial planes parallel to the line intersecting the anterior-posterior commissure (AC-PC) line. Head position was maintained with the help of individualized foam holders and monitored by video. Subjects were scanned at rest in a quiet room with low light. Smoking and consumption of alcohol, coffee, and other caffeinated beverages were not allowed for 12 hours before scanning. Eating and drinking were not allowed for 8 hours before PET scanning.
MRI was performed using a clinical 1.5-Tesla MRI system (Siemens Magnetom Avanto). T2-weighted sequences (axial T2-spin echo: repetition time [TR] ϭ 4,540 msec, echo time [TE] ϭ 97 msec, 5 mm slice thickness; axial fluid-attenuated inversion recovery: TR ϭ 9,000 msec, TE ϭ 114 msec, inversion time [TI] ϭ 2,500 msec, 5-mm slice thickness) and volumetric T1 sequences (coronal and axial T1-spin echo: TR ϭ 635 msec, TE ϭ 17 msec, 5 mm slice thickness; T1 volumetric magnetization-prepared rapid gradient echo: TR ϭ 1,900 msec, TE ϭ 3.53 msec, TI ϭ 1,100 msec, flip angle 15, 1 mm isotropic voxels) pre-gadolinium (Gd) and post-Gd chelate IV administration (7.5 mmol gadobutrol) were acquired for image registration, for brain volume measurement, and to define regions of interest (ROI) and the MRI-visible lesion load.
MRI analyses. MRI were reorientated with the horizontal line defined by the AC-PC line and the sagittal planes parallel to the midline. MRI scans were automatically segmented using the multi-atlas propagation with enhanced registration (MAPER) approach 23 into 83 anatomic regions. [25] [26] [27] This robust technique improves the quality of multi-atlas based automatic whole-brain segmentations, 28 allows the automatic segmentation of PET data in anatomic regional volumes, and is applicable even to subjects with ventriculomegaly. The MRIs were then further segmented into GM and WM tissue classes using Statistical Parametric Mapping (SPM2, Wellcome Department of Imaging Neuroscience, UCL) implemented in Matlab 6.5 (The Mathworks Inc.).
PK11195 PET analyses.
Following reconstruction of the dynamic PK11195 image volume, a summed image volume was created from the entire dynamic dataset. The input function was derived using the SUPERPK software package (Imperial Innovations). 21, 22 In brief, the supervised clustering algorithm models the time-activity curves (TAC) of each pixel as the sum of the kinetics of 4 predefined tissues (normal GM and WM, and the 2 sources of specific binding, activated microglia and the vasculature) obtained from a database of control subjects and patients. Additional signals from the skull and extracerebral muscle tissue are excluded by elimination of nonbrain voxels with the use of the coregistered GM and WM components extracted from the individual MRIs. The reference kinetic is obtained by averaging on the whole brain, whereas each pixel TAC is weighted by its normal GM index. The reference TAC is then used as input for a simplified reference region modeling approach 29 which additionally incorporates the specific (but of no interest) binding of PK11195 to the vasculature 30 and is applied to the PET dynamic volume to generate a pixel-by-pixel map of PK11195 binding potential of the specifically bound radioligand relative to the nondisplaceable radioligand in tissue (BP ND ).
PK11195 parametric images of each subject were coregistered to their respective MRI scans using the mutual information registration algorithm in the SPM2 software package. This same transformation was applied to the thresholded (probability of 0.5) GM and WM masks and to the 83 ROIs generated with the MAPER approach. Multiplication across these coregistered images and masks created BP maps, the patients' individual 83 ROIs in which then were sampled with the ANALYZE medical imaging software (version 8.1, Mayo Foundation) (for example, see figure e-1 on the Neurology ® Web site at www.neurology.org). -1 and figure 1 ). The proportion of patients with abnormally high total cortical GM PK11195 BP ND (Ͼ2 SD above total cortical GM PK11195 mean BP ND for healthy controls) was greater for the patients with SPMS (6/8 patients) than for the patients with RRMS (4/10) (figure 2 
Figure 2 Scatterplot showing individual cortical gray matter (GM) PK11195 BP ND values
Values are from groups of healthy controls (n ϭ 8), patients with relapsing-remitting multiple sclerosis (RRMS) (n ϭ 10), and patients with secondary progressive multiple sclerosis (SPMS) (n ϭ 8). Dotted line represents the healthy control mean ϩ 2 SD.
Total cortical GM PK11195 BP ND values were not significantly correlated with the duration of MS symptoms or the duration of confirmed MS diagnosis for the whole group or either patient subgroup or with the duration of secondary progressive phase for patients with SPMS. We performed a further analysis to explore whether increased GM PK11195 BP ND in specific cortical regions correlated with disability measures. We found that EDSS scores significantly correlated with precentral gyrus GM PK11195 BP ND e-2) . However, we found no correlations between WM PK11195 BP ND and EDSS and MSIS-29 scores for the whole group of patients with MS or for either of the subgroups (figure e-3) . DISCUSSION 
Using noninvasive in vivo PK11195
PET and an optimized method for modeling the signal, we have demonstrated significant increases in TSPO expression, reflecting microglial activation, in the cortical GM of patients with RRMS and patients with SPMS. Microglial activation is a prominent feature of cortical lesions in MS 1, 6 and our observations demonstrate that this can be assessed in the cortical GM in vivo. We showed that cortical GM PK11195 binding correlated with disability scores in the patients with MS with a stronger correlation for the subgroup of patients with SPMS. Moreover, we showed that the distribution of increased signal is not uniform across the cortical GM. Our results suggest that increased PK11195 BP ND in functionally eloquent anatomic regions involved in motor control and somatosensation (precentral gyrus for SPMS and postcentral gyrus for RRMS) may have particular relevance to disability.
Although PK11195 BP ND increases were also observed in WM, they did not show correlation with measures of disability, in keeping with recent studies suggesting that accumulating cortical GM pathology plays the major role in progression of both physical and cognitive disability. 8 Although it is not possible to have confirmatory postmortem data, we suggest that the distribution of increased PK11195 binding is related to the distribution of areas of enhanced cortical pathology. Previous postmortem tissue studies have shown that PK11195 binding is relatively specific for microglia and macrophages. 17 Microglia become activated in response to acute and chronic neuronal and myelin insults and are thought to contribute to tissue repair. 32, 33 However, chronic microglial activation has also been identified as an important pathologic mechanism involved in neurodegeneration in a variety of neurologic diseases, including MS. 34 Microglial activation can be the consequence of tissue damage but can also be responsible for neuronal death. [35] [36] [37] In chronic cortical GM lesions, these neurodegenerative effects may predominate and lead to progressive loss of neurons and oligodendrocytes associated with increasing disability. 6 Previous postmortem tissue studies have shown that increased microglial numbers and increased activation are associated with variable degrees of axonal/ neuritic injury, demyelination, and neuronal loss in the cortical GM in the progressive stages of MS. 5, 6 However, it is as yet unclear how early during the course of MS these degenerative events begin. Future longitudinal in vivo studies relating microglial activation to measures of local cortical atrophy or dysfunc- tion and the progression of disability in individual subjects (particularly in the context of treatments that reverse disability) 38 should contribute to improve our understanding of the consequences of cortical pathology at different disease stages.
We observed a striking regional distribution of increased PK111195 binding across the cortex. Neuropathologic studies have highlighted that cortical GM lesions can occur as long ribbons of subpial demyelination and are more commonly found in particular cortical regions. 1, 3, 6 The presence of substantial meningeal inflammation in some cortical sulci is associated with exacerbated cortical GM demyelination and this has led to the suggestion that microglial activation and cortical demyelination may occur in a gradient fashion from the pial surface inwards. 5, 6, 12 Thus, there may be specific anatomic regions with greater potential to initiate, propagate, or sustain an inflammatory cascade in MS.
Our analysis suggested a correlation between higher EDSS scores and increased microglial activation in the precentral gyrus in patients with SPMS. This observation is consistent with a recent postmortem study showing increased density of activated microglia and substantial neuronal loss in GM lesions of the precentral gyrus of SPMS cases exhibiting significant meningeal inflammation. 6 Neuronal loss and increased density of activated microglia were associated with both the subpial lesions and the normalappearing nondemyelinated GM, 6 as reflected in the widespread increase in the cortical GM PK signal observed in the present study. Changes in cortical GM PK signal may reflect a combination of direct effects of proinflammatory and cytotoxic mediators derived from the meninges, degenerative changes due to downstream WM lesions, and GM demyelination.
We also found a correlation between higher EDSS scores and increased microglial activation in the postcentral gyrus for the subgroup of patients with RRMS. Previous studies have shown significant GM volume loss in the postcentral gyrus of patients with RRMS.
39,40 Although we did not identify any correlation between local GM volume and PK11195 BP ND , we believe that further investigations using more precise measures of voxel-wise GM concentration or cortical thickness are necessary to test this further. In addition, increased PK11195 binding was seen in the middle frontal, anterior orbital, fusiform, and parahippocampal gyri in the patients with RRMS and a broader range of cortical regions extending to superior parietal, lingual and anterior superior, medial and inferior temporal gyri in patients with SPMS. These large, highly associative cortical regions are involved to some degree in many cognitive processes. While nonspecific to support this contention directly, higher MSIS-29 scores correlated with increases in total cortical GM microglial activation. It is intriguing to speculate that such widespread cortical microglial activation may contribute to cognitive deficits in MS.
e1
A unique feature of our study is the focus on cortical pathology in MS. Microglial activation may be less prominent in GM than in WM lesions, 1 which may account in part for why previous studies have reported only on WM changes. [17] [18] [19] In our study we were able to take advantage of improved modeling and anatomic registration methods that have improved sensitivity for detection of cortical signal. Modeling the signal arising from the specific binding of PK11195 to TSPO has previously proved challenging.
e2,e3 The use of SUPERPK allows the quantification of specific binding with robust quantitative implementation at the pixel level. 21 In addition, the atrophy and ventriculomegaly observed in MS patient brains confound accurate registration and anatomic segmentation. The MAPER approach has been designed to accurately address this issue. 23 Nonetheless, there are limitations of our study. 1) Our small sample is limiting the potential to confidently characterize relationships between PK11195 BP ND and disability measures and to extend the correlations with other indices, such as MRI. Also, this is a cross-sectional study and therefore, not able to directly test for temporal changes in microglia activation with the pathologic evolution of MS. 2) PK11195 nonspecifically binds to other glial cells such as astrocytes. e4,e5 3) While a variability of only 10% was found between scans for Alzheimer disease (AD), 21 different biological factors could influence the reproducibility of measurements for patients with MS. Test-retest data on patients with MS will be needed for explorations of any applications to decision-making for individual patients or for prospective powering of clinical trials using these measures. 4) PET image analysis and quantification of PK11195 can be confounded by the vascular binding of the tracer and, in patients with AD, blood-brain barrier disruption causes a small reduction in binding. 30 However, here by using SUPERPK 21, 22, 30 we have used a reference region and not plasma input. 5) Patients with MS have greater GM atrophy with disability progression, although this should bias toward an apparent reduction in BP due to partial volume effects arising from the limited spatial resolution of the scanner, rather than the greater BP we report with SPMS relative to RRMS. Measurements of BP should be able to be made more accurate in future studies by higher resolution scanning and accounting explicitly for any variations in local gray matter thickness in the kinetic model.
